Detection and treatment initiation for depression and alcohol use disorders: facility-based cross-sectional studies in five low-income and middle-income country districts

Sujit D Rathod, Tessa Roberts, Girmay Medhin, Vaibhav Murhar, Sandesh Samudre, Nagendra P Luitel, One Selohilwe, Joshua Ssebunnya, Mark J D Jordans, Arvin Bhana, Inge Petersen, Fred Kigozi, Juliet Nakku, Crick Lund, Abebaw Fekadu, Rahul Shidhaye

ABSTRACT

Objectives To estimate the proportion of adult primary care outpatients who are clinically detected and initiate treatment for depression and alcohol use disorder (AUD) in low-income and middle-income country (LMIC) settings.

Design Five cross-sectional studies.

Setting Adult outpatient services in 36 primary healthcare facilities in Sodo District, Ethiopia (9 facilities); Sefore District, India (3); Chitwan District, Nepal (8); Dr Kenneth Kaunda District, South Africa (3); and Kamuli District, Uganda (13).

Participants Between 760 and 1893 adults were screened in each district. Across five districts, between 4.2% and 20.1% screened positive for depression and between 1.2% and 16.4% screened positive for AUD. 96% of screen-positive participants provided details about their clinical consultations that day.

Primary outcomes Detection of depression, treatment initiation for depression, detection of AUD and treatment initiation for AUD.

Results Among depression screen-positive participants, clinical detection of depression ranged from 0% in India to 11.7% in Nepal. Small proportions of screen-positive participants received treatment (0% in Ethiopia, India and South Africa to 4.2% in Uganda). Among AUD screen-positive participants, clinical detection of AUD ranged from 0% in Ethiopia and India to 7.8% in Nepal. Treatment was 0% in all countries aside Nepal, where it was 2.2%.

Conclusions The findings of this study suggest large detection and treatment gaps for adult primary care patients, which are likely contributors to the population-level mental health treatment gap in LMIC. Primary care facilities remain unfulfilled intervention points for reducing the population-level burden of disease in LMIC.

BACKGROUND

Mental, neurological and substance use disorders (MNS) contribute significantly to the Global Burden of Disease and account for 1 in every 10 lost years of health globally. In 2010, the absolute disability-adjusted life-years (DALYs) due to MNS disorders was 258 million DALYs, which was 10.4% of the total disease burden. MNS disorders were also the leading cause of years lived with disability globally. In addition, MNS disorders act as a significant risk factor for premature death and also account for substantial adverse social and economic consequences. Depression accounts for 40.5% of DALYs caused by mental and substance use disorders while alcohol use disorders (AUDs) account for 9.6%.

In low-income and middle-income countries (LMICs) the population-level treatment gap is estimated to be between 76.3% and 91.9% for depression and between 94.9% and 97.2% for AUD. There is an emerging evidence base demonstrating that depression and AUD can be treated by primary care providers in LMIC; WHO’s mhGAP guidelines support integration of mental health services into primary care as a means of narrowing the treatment gap. People affected by depression and AUD often present...
in primary health care facilities\(^4\) \(^9\) though not specifically for these disorders. These disorders co-occur with both acute and chronic medical problems; an untreated mental health disorder worsens the prognosis for the comorbid condition.\(^10\) \(^11\) The population-level treatment gap can be reduced by enhancing the capacity of primary care staff to detect, diagnose and treat these disorders.\(^12\) Clinical detection of depression is estimated to be 47% from a meta-analysis of 41 studies conducted in primary care settings\(^13\) and 42% for AUD from a meta-analysis of 12 studies.\(^14\) However, these meta-analyses were not able to identify studies conducted in LMIC settings, where the majority of people with depression and AUD in the world live, and where a paucity of mental health in the pre-service training of general health care providers as well as competing demands in under-resourced health care systems likely compromise the ability of clinicians to detect mental disorders. Little is therefore known regarding the detection levels of depression and AUD in primary care settings in LMICs.

The aims of this report were to estimate the proportion of adult primary care outpatients who are clinically detected and initiate treatment for depression and for AUD in LMIC settings.

### METHODS

**Context, setting and participants**

PRIME is a 6-year multicountry research programme consortium which, in collaboration with national and district Ministries of Health, has developed Mental Health Care Plans to support delivery of services for mental disorders in the public sector in Ethiopia (Sodo District), India (Sehore District, Madhya Pradesh State), Nepal (Chitwan District), South Africa (Dr Kenneth Kaunda District, North West Province) and Uganda (Kamuli District).\(^15\) \(^16\) Two key research questions of the PRIME evaluation, detailed in a separate report,\(^17\) were to assess the change in detection and change in initiation of treatment among adults presenting in primary health facilities, as a consequence of implementing the district mental health care plans. These questions were investigated by conducting cross-sectional facility-based patient surveys before and after the mental health care plan implementation. The two populations of interest for the study were the adult patients who screened positive (1) for depression and (2) for AUD.

Details about the study settings and clinics are in table 1.

The choice of included clinics was determined by the availability of staff who were planned to have authority to detect/diagnose, prescribe and/or refer for depression

### Table 1 Geographic and health facility characteristics of PRIME implementation areas, 2013–2014

| Country   | Ethiopia | India | Nepal | South Africa | Uganda |
|-----------|----------|-------|-------|--------------|--------|
| Implementation area | Sodo District | Sehore and Shyampur subdistricts of Sehore District, Madhya Pradesh | Chitwan District* | Orkney catchment area of Matlosana subdistrict of Dr Kenneth Kaunda District, Northwest Province | Kamuli District |
| Population | 161 952 | 212 192 | 108 368 | 90 000 | 518 200 |
| Area, km\(^2\) | 867 | 1039 | 342 | 31 | 4278 |
| # and type of health facility | 8 public and 1 private health clinics | 3 CHC | 9 health posts and 1 PHC† | 1 CHC and 3 PHC clinics‡ | 12 health centres (levels III and IV) 1 primary care department in the district hospital |

*Implementation area consists of 10 of the 38 Village Development Committees/Municipalities of Chitwan District.
†222 study participants from 2 of the 10 health facilities are excluded from analysis.
‡One of the three PHC clinics was an implementation pilot site and was excluded from study data collection.

CHC, community health centre; PHC, primary health care centre.
and AUD, which, per the respective country’s mental health care plan included clinics with health officers, medical officers, health assistants and auxiliary health workers, nurses and doctors. In South Africa, one of the PHC clinics was excluded from the study due to mental health care plan training occurring prior to the baseline survey round. In South Africa, nurses in the primary care clinics could refer suspected cases to a physician (for both disorders) and provide brief counselling (for non-dependent AUD) and so these clinics were included. Only patients attending for chronic care services (eg, HIV, tuberculosis, diabetes, hypertension, etc) were eligible for this study, reflecting eligibility for treatment in accordance with the South African mental health care plan. In Nepal, clinicians working in two clinics received mental health training prior to the baseline survey round; these clinics are included for clinical-level descriptive reporting but participants from these clinics are excluded for analysis here. All clinics were government run, aside one in Ethiopia.

Sample size

For each country and disorder the sample size was set to have 80% power and a two-sided alpha of 0.05 for the two primary aims: (1) to detect a change in detection and (2) to detect a change in initiation of evidence-based treatment for depression and for AUD between the baseline and follow-up round. The baseline round was set prior to implementation of the mental health care plan and follow-up round was scheduled to start at least 18 months later, which assumed the plan had been fully embedded for several months. Country teams in Nepal and Uganda planned to conduct an interim survey round immediately after embedding, to assess the short-term effect of implementation on detection and treatment. Findings from interim and follow-up surveys will be detailed in future reports. Depending on country, the baseline level of detection was assumed to be 0%-5%, and at follow-up targeted to reach 20%-30%. The required sample size was adjusted to account for the possibility of false positives generated by screening tools, using site-specific figures for the positive predictive value. Within each country, whichever disorder required the higher sample size dictated the sample size. This sample size was increased by a factor of 2–3× to facilitate equity analyses, for example, comparisons of outcomes by sex or by socioeconomic status. The target sample sizes for each country in each study round were 1000 in Ethiopia, 760 in India, 1400 in Nepal, 1200 in South Africa and 1800 in Uganda. Within each country the total target sample size was then allocated by clinic in proportion to measures of clinic outpatient volume, such that busier clinics were allocated a larger recruitment target than less busy clinics.

Details of the sampling and data collection procedures are given in table 2.

Sampling and recruitment

Inclusion criteria for participation were as follows: above age of majority in the country (ie, 16 years or 18 years); fluency in a local study language; time and ability to complete the full interview; and willingness to provide informed consent. Exclusion criteria were as follows: incapacity to provide informed consent (eg, presence of severe intellectual disability, currently experiencing an acute medical issue). The research team for each country trained its interviewers to assess eligibility.

Logistic and cultural constraints dictated the sampling procedure within each country, meaning that random selection for a representative sample was not always possible. In Ethiopia and Uganda, to minimise disruption, consecutive sampling of all eligible patients on registration minimised the amount of time research staff spent in the clinics. In South Africa, research staff provided a group orientation to the study to all patients in the waiting room, and then asked interested patients to self-nominate for recruitment. In India, research assistants approached every fifth patient registering at reception and assessed them for eligibility. Among eligible patients approached, >94% consented to participate in all countries.

Data collection procedures

The facility interview comprised a screening questionnaire, an exit questionnaire and/or a clinical consultation form. Interviewers administered the two-part screening questionnaire, with part 1 used to identify probable cases. For probable cases and optionally for probable non-cases, interviewers completed part 2 of the screening questionnaire. For these same participants, the interviewer completed the exit questionnaire with the participant and/or requested a consultation form from that participant’s clinician. In Uganda, patients maintained their own medical files in a notebook which is handed over to clinicians during consultations, and so the clinical consultation form data were synonymous with exit questionnaire data. The data collection flow chart for each country is shown in online supplementary figures 1a-e.

The sections within the screening interview questionnaire are described in table 3.

Data collection measures

Part 1 of the screening questionnaire consisted of sections on sociodemographic characteristics, screening for depression, depression symptoms in the past 12 months (aside in Ethiopia) and screening for AUD. A probable case of depression was a participant who was Patient’s Health Questionnaire (PHQ-9) positive or had recent depression symptoms, and a probable case of AUD was a participant who was Alcohol Use Disorder Identification Test (AUDIT) positive. Probable cases completed disorder-specific sections about recent (12 months) history of treatment seeking for their most recent episode of symptoms, and about internalised stigma. Part 2 consisted sections about sociodemographic characteristics and disability status. The exit questionnaire and clinical consultation form were thematically similar, and consisted of a mix of open-ended and closed-ended questions about that day’s clinical consultation, and specifically
about diagnoses, advice, referrals and prescriptions. Each country developed their own exit questionnaire and clinical consultation form to enable data collection by interviewers with the participant and by the clinician directly, respectively, in recognition of the context-specific nature of patient–clinician interactions and the local idioms of distress. In addition to the questionnaire items described here, which were largely consistent across PRIME country sites, research teams included country-specific questions and sections, which will be described in future reports. See PRIME website (http://www.prime.uct.ac.za) for the purpose-built sections of the PRIME questionnaires.

### Mental health measures

The denominators for the primary outcome measures consist of those participants who screen positive for depression or for AUD using the PHQ-9 and AUDIT, respectively. The PHQ-9 is a widely used screening tool that has been validated for use in all five countries.18–22 In this study, Cronbach’s alpha for the PHQ-9 ranged between 0.74 in India and 0.80 in Nepal. A score of 10 or more on the PHQ-9 screen was considered a positive screen. The AUDIT tool has been validated in India, Nepal and South Africa23–25 and in countries neighbouring Uganda.26 27 In this study, Cronbach’s alpha for AUDIT ranged from 0.66 in Uganda to 0.88 in Nepal. An AUDIT score of ≥20 was considered to indicate alcohol dependence, while scores of 16–19 and 8–15 were classified as harmful and hazardous drinking, respectively. A score of 8 or more in Ethiopia, India and Uganda, 9 or more in Nepal and 16 or more in South Africa was considered a positive screen. The higher cut-off score in South Africa was set to account for services being targeted to those with harmful and dependent alcohol use.

### Outcome assessment

The numerators for the primary outcome measures were derived from participant exit questionnaire data when available (India, Nepal, South Africa, Uganda), and alternatively from the clinician consultation form data (Ethiopia). Given the sparse level of detail patients were expected to recall and/or clinicians were expected to record, cross-country variation in the terminology around detection and treatment, as well as expected low levels

| Table 2  | Sample selection and data collection procedures for facility surveys, 2013–2014 |
|----------|----------------------------------------------------------------------------------|
| **Country site** | **Ethiopia** | **India** | **Nepal** | **South Africa** | **Uganda** |
| **Survey dates** | June–July 2013 | August–October 2013 | September 2013–February 2014 | February–April 2014 | July–November 2013 |
| **Study language** | Amharic | Hindi | Nepali | English, setswana | English, Luganda |
| **Recruitment/sampling method** | Consecutive sampling of adults at registration | Systematic sampling of every fifth adult at registration | Random selection of one adult from those who arrived since last interview started | Opportunistic sampling of adult volunteers in chronic care clinic waiting area | Consecutive sampling of adults at registration |
| **Consent documented with** | Signature or thumbprint | Signature or thumbprint | Signature or verbal affirmation | Signature or signed ‘X’ with independent witness signature | Signature or verbal affirmation |
| **# approached** | 1014 | 760 | 1553 | 9780 | 1922 |
| **# eligible** | 1014 | 760 | 1553 | 9780 | 1922 |
| **# consented (% consent rate)** | 1014 (100) | 760 (100) | 1474 (94.9) | 1322 (100) | 1893 (98.5) |
| **Questionnaire data collection mode** | Paper-and-pencil, double data entry with EpiData 3 | Android mobile device | Android mobile device | Android mobile device | Android mobile device |
| **Depression screen positive is Patient’s Health Questionnaire ≥ 10** | 10 | 10 | 10 | 10 | 10 |
| **Alcohol use disorder screen positive is Alcohol Use Disorder Identification Test ≥ 8** | 8 | 8 | 9 | 16 | 8 |
| **Clinical consultation form** | Purpose-built form | Extracted from clinical records maintained at the facility | Purpose-built form | Extracted from clinical records | Consultation notes extracted from patient’s notebook as part of the exit questionnaire |
of detection and treatment at baseline, highly sensitive and non-specific coding criteria, detailed in Table 4, were adopted and used for the outcomes’ numerators. These criteria were informed by WHO’s mhGAP guidelines.7

Outcome assessors (TR, SS and SDR) independently double-coded the outcomes for detection (yes/no) and treatment (Yes/No) with 99% initial scoring agreement. Disagreements were resolved through further discussion.

### Analysis
First, the sociodemographic characteristics and mental health screening scores of participants were summarised

### Table 4 Criteria used to assess detection and treatment of depression and alcohol use disorders in the PRIME facility detection study, 2013–2014

| Detection of depression |Treatment of depression |
|-------------------------|------------------------|
| **Included:** | **Included:** |
| ► Diagnosis of ‘depression’ | ► Prescription of SSRI (eg, fluoxetine) |
| ► Diagnosis of ‘stress’, ‘distress’, ‘behavioural problem’, ‘mental disorder’ or ‘psychiatric problem’ | ► Referral to a mental health specialist |
| ► Diagnosis assumed if unambiguous depression treatment given | ► Advice on stress reduction or management—only with depression diagnosis |
| | ► Prescription of tricyclic antidepressant (eg, amitriptyline) only with depression diagnosis |
| | ► Referral to counselling or talking treatment—only with depression diagnosis |
| | ► Diazepam prescription |
| | ► Non-specific referrals (eg, ‘hospital’) |
| **Excluded:** | **Excluded:** |
| ► Diagnosis of ‘anxiety’, ‘insomnia’, ‘tension headache’, ‘stress headache’, ‘schizophrenia’, ‘epilepsy’, ‘bipolar’, ‘central nervous system problem’ | |

| Detection of alcohol use disorder | Treatment of alcohol use disorder |
|-----------------------------------|----------------------------------|
| **Included:** | **Included:** |
| ► Diagnosis of ‘AUD’, ‘alcohol problem’ or ‘drinking problem’ | ► Referral to a mental health or addictions specialist |
| ► Diagnosis assumed if unambiguous AUD treatment given | ► Prescription of diazepam or vitamin B—only with AUD diagnosis |
| | ► Counselling or talking treatment—only with AUD diagnosis |
| | ► Non-specific referrals (eg, ‘hospital’) |
| **Excluded:** | **Excluded:** |
| ► Drug abuse or other substance use problems | |

AUD, alcohol use disorder; SSRI, selective serotonin reuptake inhibitor.
by presenting the median and IQR for continuous measures and counts and percentages for categorical measures. Second, for depression screen-positive participants, the numbers and proportions who had outcome data were detected for depression and who had initiation of minimally adequate evidence-based treatment were reported. The same figures were reported for AUD screen-positive participants and AUD. Finally, depression and AUD detection figures are reported for participants who were depression and AUD screen-negative and who did not have depression symptoms over the past 12 months. These latter figures are indicators—though not definitive evidence—for either misdiagnosis or overdiagnosis. All analyses were conducted in Stata 14.1 (StataCorp), and stratified by country. (see online supplemental file ‘stata do file code.docx’)

**Ethics**

All participants gave written or verbal informed consent prior to being interviewed (table 2). The informed consent form made clear there would be no negative effects for non-participation. In South Africa, participants were provided a 30 rand (US$ 2.80) supermarket voucher as a token of appreciation. In all countries, participants who endorsed questionnaire items about suicidality were referred to a provider in the clinic.

The institutional review boards of the WHO (Geneva, Switzerland), University of Cape Town (South Africa), College of Health Sciences of Addis Ababa University (Ethiopia), Indian Council of Medical Research (New Delhi, India), Sangath (Goa, India), Nepal Health Research Council (Kathmandu, Nepal), Makerere University (Kampala, Uganda) and the National Council of Science and Technology (Kampala, Uganda) reviewed and approved the protocols and informed consent procedures for this study.

**Patient involvement**

The PRIME interventions and evaluations were informed through Theory of Change workshops held in each country.28 These workshops included national-level and district-level representatives, health service providers and, in some countries, mental health service users.

**RESULTS**

The demographic and mental health screening characteristics of participants are detailed in table 5.

Ages ranged from a median of 28 years in Uganda to 46 years in South Africa. The majority of participants in all countries were female, from 51% in India to 79% in Uganda. The proportion of participants who screened positive for depression ranged between 20% in India to 4.2% in Uganda, for depression symptoms in the past 12 months ranged between 8% in Uganda to 14% in India, and for AUDIT between 1% in Uganda and 16% in Ethiopia. These probable cases were asked to complete the Exit interview and/or their clinicians asked to complete a consultation form. Outcome data were available for 96% of these participants (from clinical consultation forms or exit questionnaires), though exit questionnaire completion was lower for depression screen-positive participants in Uganda (48/80, 60%), and AUD screen-positive participants in South Africa (38/43, 90%) and Uganda (18/23, 78%), respectively. Non-completion was primarily due to participants having to leave the clinic immediately or the

| Table 5 Demographic and mental health characteristics for facility detection survey participants, 2013–2014 |
|---------------------------------------------------------------|
| Country site (sample size) | Ethiopia (n=1014) Median (IQR) or n (%) | India (n=760) Median (IQR) or n (%) | Nepal* (n=1252) Median (IQR) or n (%) | South Africa (n=1322) Median (IQR) or n (%) | Uganda (n=1893) Median (IQR) or n (%) |
| Age, years | 30 (23–45) | 37 (27–51) | 36 (27–50) | 46 (37–56) | 28 (22–37) |
| Female | 551 (54.3) | 386 (50.8) | 813 (64.9) | 992 (75.0) | 1500 (79.2) |
| Education | | | | | |
| Less than primary | 692 (68.3) | 381 (50.1) | 444 (35.5) | 308 (23.3) | 174 (9.2) |
| Primary | 230 (22.7) | 186 (24.5) | 253 (20.2) | 829 (62.7) | 1113 (58.8) |
| Secondary or more | 91 (9.0) | 193 (25.4) | 555 (44.3) | 185 (14.0) | 606 (32.0) |
| PHQ-9 score | 4 (1–7) | 6 (4–9) | 4 (2–7) | 3 (1–6) | 2 (1–4) |
| PHQ-9 positive† | 117 (11.5) | 153 (20.1) | 186 (14.9) | 107 (8.1) | 80 (4.2) |
| Depression symptoms in past 12 months | 110 (14.5) | 174 (13.9) | 157 (11.9) | 159 (8.4) |
| AUDIT score | 2 (0–5) | 0 (0–0) | 0 (0–1) | 0 (0–4) | 0 (0–0) |
| Alcohol abstinent | 275 (27.1) | 659 (86.7) | 849 (67.8) | 724 (54.8) | 1475 (77.9) |
| AUDIT positive | 166 (16.4) | 35 (4.6) | 92 (7.3) | 43 (3.2) | 23 (1.2) |
| Dependent alcohol use | 37 (3.6) | 3 (0.4) | 32 (2.6) | 21 (1.6) | 2 (0.1) |
| *Excluding 222 patients from two clinics. AUDIT, Alcohol Use Disorder Identification Test; PHQ, Patient’s Health Questionnaire, |

on 17 October 2018 by guest. Protected by copyright.
interviser being unable to locate the participant after
their consultation.

The proportions of screen-positive participants who were detected and who started treatment are presented
Table 6.

Among depression screen-positive participants, detection of depression ranged from 0% in India to 11.7% in
Nepal. Small proportions of screen-positive participants received treatment (0% in Ethiopia, India and South
Africa to 4.2% in Uganda). Among AUD screen-positive participants, detection of AUD ranged from 0% in Ethio-
pia and India to 7.8% in Nepal. Treatment was 0% in all countries aside Nepal, where it was 2.2%.

For probable non-cases, detection of depression ranged from 0/557 (0.0%) in India to 3/74 (4.0%) in Nepal, and
detection of AUD ranged from 0/557 (0.0%) in India to 2/74 (2.7%) in Nepal. Treatment was almost entirely
absent (see Table 7).

**DISCUSSION**

This study establishes the magnitude of the detection gap for adults attending primary care in diverse LMIC settings. There were low levels of detection of depression from screen-positive participants in Ethiopia, Nepal, South Africa and Uganda and no detection in India. There was no detection of AUD among screen-positive participants outside Nepal and Uganda. Conversely, there was almost no evidence of misdiagnosis or overdiagnosis of depression or AUD among participants who screened negative.

The detection figures observed here are substantially lower than the average figures found by Mitchell et al for detection of depression (47%) and for AUD (42%) by primary care providers in high-income countries.13 14 As studies of clinical detection in LMIC settings were not available for these meta-analyses, this study fills a key gap in our understanding of the detection gap globally. The consistency of findings across these five diverse settings likely provides insight across LMIC settings generally. The health service organisations in this study varied considerably in catchment size, services offered and provider types (Table 1), and facility attendees varied considerably by age, sex, educational attainment and symptom severity (Table 5). Yet detection was consistently poor. These findings provide insight into how the population-level treatment gap in LMIC is at least partially attributable to a facility-level detection gap.

Table 6 Detection and treatment among screen-positive adults in PRIME implementation clinics, 2013–2014

| Country site | Ethiopia (n=117) | India (n=153) | Nepal (n=179) | South Africa (n=103) | Uganda (n=48) |
|--------------|-----------------|-------------|-------------|---------------------|-------------|
| **Depression** | | | | | |
| Outcome data collected/screen positive | 117/117 | 153/153 | 179/186 | 103/107 | 48/80 |
| Detected, n (%), 95% CI | 12/117 (10.3, 5.9 to 17.2) | 0/153 (0.0) | 21/179 (11.7, 7.8 to 17.3) | 6/103 (5.8, 2.6 to 12.4) | 2/48 (4.2, 1.0 to 15.4) |
| Treatment initiated, n (%), 95% CI | 0/117 (0.0) | 0/153 (0.0) | 1/179 (0.5, 0.0 to 3.9) | 0/103 (0.0) | 2/48 (4.2, 1.0 to 15.4) |
| **Alcohol use disorder** | | | | | |
| Outcome data collected/screen positive | 166/166 | 35/35 | 90/92 | 38/43 | 18/23 |
| Detected, n (%), 95% CI | 0/166 (0.0) | 0/35 (0.0) | 7/90 (7.8, 3.7 to 15.6) | 0/38 (0.0) | 1/18 (5.6, 0.7 to 32.2) |
| Treatment initiated, n (%), 95% CI | 0/116 (0.0) | 0/35 (0.0) | 2/90 (2.2, 0.5 to 8.6) | 0/38 (0.0) | 0/18 (0.0) |

Table 7 Detection and treatment among probable non-cases in PRIME implementation clinics, 2013–2014

| Country site (# depression and alcohol use disorder screen-negative and no depression symptoms in 12 months) | Ethiopia (n=752) | India (n=557) | Nepal (n=74) | South Africa (n=113) | Uganda (n=332) |
|-------------------------------------------------|-----------------|-------------|-------------|---------------------|-------------|
| **Depression** | | | | | |
| Detected, n (%) | 16/752 (2.1) | 0/557 (0.0) | 3/74 (4.1) | 4/113 (3.5) | 2/332 (0.6) |
| Treatment initiated, n (%) | 0/752 (0.0) | 0/557 (0.0) | 0/74 (0.0) | 3/113 (2.6) | 1/332 (0.3) |
| **Alcohol use disorder** | | | | | |
| Detected, n (%) | 0/752 (0.0) | 0/557 (0.0) | 2/74 (2.7) | 2/113 (1.8) | 1/332 (0.3) |
| Treatment initiated, n (%) | 0/752 (0.0) | 0/557 (0.0) | 0/74 (0.0) | 0/113 (0.0) | 1/332 (0.3) |
While detection levels were low, the facility-level treatment gap approached 100% in most settings. The treatment outcome definitions used here were broad and included provision of advice or referrals to specialist care, both of which clinicians were able to dispense prior to implementation of the PRIME mental health care plans. The first barrier for providing treatment at the health facility is detection, and, as reported above, across all settings detection levels were extremely low. The findings of this study indicate consistent missed opportunities for providing evidence-based care across these diverse LMIC settings. Improving clinical detection and treatment of depression and AUD by primary care providers remains an area where intervention development is required; the PRIME consortium will evaluate its own interventions—the plans for which have described in detail—in follow-ups to this report.

The PRIME Facility Detection study uses widely validated screening tools to identify probable cases. While diagnostic interviews are the gold standard for identifying cases, screening tools are usable by trained interviewers rather than clinicians, and so the methods used here are more easily replicable for monitoring and evaluation activities in other LMIC settings. Our outcome data were collected directly from the participants and clinicians rather than from a health management information system, which is also a replicable monitoring method for LMIC settings.

There are several limitations to our study. First, screening tools (PHQ-9 and AUDIT) were used to identify probable cases of depression and AUD; an unknown number of screen-positive cases are actually false positive cases. Further, a 100% detection figure is not a desirable goal as it indicates diagnosis among false positive cases. Screening misclassification is likely to be similar in the follow-up round, and so the denominators for detection and treatment are equally biased across rounds and allow a valid comparison across time to be made. Second, non-random sampling was used to select patients in some countries. While the samples may not be representative of the facility-attending population, the same sampling plan will be used in follow-up rounds, enabling valid comparisons for the study’s primary findings. And, given the non-random sampling and use of screening tools it is not appropriate to interpret the proportions of participants who screen positive as prevalence figures for cross-country comparisons. The loss to follow-up for screen-positive participants in Nepal, South Africa and Uganda could result in biased findings as the diagnostic characteristics of lost participants are unknown.

A third limitation concerns the outcome definitions for detection and treatment. Given the limitations of using patient-reported and clinician-reported data, with issues around recall and specificity, we opted to use extremely sensitive yet non-specific thresholds of evidence for coding detection or treatment as having occurred. The detection and treatment figures reported here should therefore be regarded as the upper bound of possibility; some of those coded as having been detected with depression may have other mental health disorders, and some of those coded as having treatment may not have what is considered to be minimally adequate evidence-based care. Again, the bias due to these misclassifications will be equal in the follow-up round. Use of cross-country coding criteria facilitates comparisons across diverse settings, and in future reports each country can use these criteria and/or develop their own more locally appropriate and specific criteria. This process has been completed in Sodo District, Ethiopia, where detection outcomes have been reported separately for using specific criteria for depression and non-specific criteria for common mental disorder.34

We plan to repeat this survey in each of the implementation sites. By comparing the baseline versus follow-up figures within each country, we will be able to determine whether the level of detection and level of initiation of evidence-based treatment for depression and for AUD has increased after implementing mental health care plans. Further to this we will compare the change in detection among probable non-cases (table 7), which is an indicator of inappropriate diagnosis; district health manager can use two detection figures to recalibrate their training and supervision systems. Also using follow-up data, we will also be able to assess whether the improved detection and improved treatment provision is equitable by age, sex and other socioeconomic factors. And, with the help of Theory of Change framework and process evaluation data collected over the implementation phase,17 we will try to explain the reasons for improvement/non-improvement of detection and initiation of treatment for depression and for AUD, along identifying with the factors relating to detection. As each country developed its own Theory of Change framework, it will be possible to contrast five frameworks with five sets of follow-up findings, and then to identify the essential characteristics of an effective strategy to improve detection.

Further research can identify the patient-level, clinician-level and system-level characteristics associated with detection as a means of further refining interventions. Some of these characteristics are already potential targets for intervention and have been identified in previous studies: on the patient level, those who have higher level of perceived need35 and lower levels of internalised stigma more are likely to receive a diagnosis. On the clinician level, detection improves with longer consultation time,36 adequate training, a stronger therapeutic alliance13 and with contractual incentives.30 And on the health system level, detection is likely to improve with the availability of medications and health providers at PHC level who have the authority to prescribe psychotropic medication, as well as referral pathways to counsellors. Also important are buy-in and support from leadership who give priority to mental health,13 governance and supervisory structures to develop and execute standardised protocols,30 and a functional health management information system40 to monitor and feedback.
on clinical activity. A combination of these patient-level, clinician-level and system-level characteristics may explain some of the substantially lower detection figures for depression and AUD found here from our LMIC settings compared with those found in meta-analyses by Mitchell et al in HIC settings.

CONCLUSION

The findings of this study suggest large detection and treatment gaps for adult primary care patients, which are likely contributors to the population-level mental health treatment gap in LMIC. Primary care centres remain unfulfilled intervention points for reducing the population-level burden of disease in LMIC.

Author affiliations

1 Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK
2 Centre for Global Mental Health, Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK
3 Department of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
4 Aklilu Lemma Institute of Pathology, Addis Ababa University, Addis Ababa, Ethiopia
5 Sangath, Bhopal, Madhya Pradesh, India
6 Centre for Chronic Conditions and Injuries, Public Health Foundation of India, New Delhi, India
7 Transcultural Psychosocial Organization (TPO), Kathmandu, Nepal
8 Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
9 Makerere University/Butabika National Referral and Teaching Mental Hospital, Kampala, Uganda
10 Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK
11 Health Systems Research Unit, South African Mental Health Research Council, Cape Town, South Africa
12 Department of Psychiatry and Mental Health, Alan J Fisher Centre for Public Mental Health, University of Cape Town, Cape Town, South Africa
13 Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
14 Global Health & Infection Department, Brighton and Sussex Medical School, Brighton, UK
15 Centre for Mental Health, Public health foundation of India, New Delhi, India
16 CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht, The Netherlands

Acknowledgements

Thanks to Katamba Mutya, Nabukko Sarah, Kirangi Juliet, Kasirir Joweria, Namwase Suzan and Mwebesa Julius in Uganda; Tasneem Kathree, Palessa Mothibedi, Primrose Mathakga and Deanna Carter in South Africa; Anup Adhikari in Nepal; and the study participants.

Contributors

Conceptualisation: SDR, MJ, IP, FK, JN, CL, AF and RS. Design: SDR, TR, GM, NL, AB, IP, FK, JN, CL, AF and RS. Data analysis: TR, GM, VM, SS, NPL, OS and JS. Data synthesis: SDR, CL and RS. Drafting SDR, TR, CL and RS. Critical revision: GM, VM, SS, NPL, OS, JS, MJ, AB, IP, FK, JN, CL, AF and RS. Final approval: SDR, TR, GM, VM, SS, NPL, OS, JS, MJ, AB, IP, FK, JN, CL, AF and RS. Accountability: SDR, TR, GM, VM, SS, NPL, OS, JS, MJ, AB, IP, FK, JN, CL, AF and RS.

Funding

This study is an output of the PRogramme for Improving Mental health carE (PRIME). The material has been funded by UKaid from the UK Government (Department of International Development).

Disclaimer

The views expressed do not necessarily reflect the UK Government’s official policies. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests

None declared.

Patient consent

Not required.

Ethics approval

WHO (Geneva, Switzerland), University of Cape Town (South Africa), College of Health Sciences of Addis Ababa University (Ethiopia), Indian Council of Medical Research (New Delhi, India), Sangath (Goa, India), Nepal Health Research Council (Kathmandu, Nepal), Makerere University (Kampala, Uganda), and the National Council of Science and Technology (Kampala, Uganda)

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

Statistical code (Stata) is available as supplementary material. While we cannot make the dataset publicly available, we will consider all request to provide a minimal dataset to interested researchers via the PRIME consortium Expression of interest form here: http://www.prime.uc.ac.za/contact-us.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Patel V, Chisholm D, Parikh R, et al. DCP MNS Author Group. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet 2016;387:1672–85.
2. Liu NH, Daumit GL, Dua T, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 2017;16:30–40.
3. Bloom D, Cafero E, Jané-Llopis E, et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum, 2011.
4. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet 2013;382:1575–86.
5. Rathod SD, de Silva MJ, Ssebunya J, et al. Treatment contact coverage for probable depressive and probable alcohol use disorders in four low- and middle-income country districts: the PRIME cross-sectional community surveys. PLoS One 2016;11:e0162038.
6. Dua T, Barber C, Clark N, et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med 2011;8:e1001122.
7. World Health Organization. mhGAP Intervention Guide - Version 2.0 for mental, neurological and substance use disorders in non-specialised health settings. Geneva: World Health Organization, 2016.
8. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85–94.
9. Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995;4:99–105.
10. Prince M, Patel V, Saxena S, et al. No health without mental health. The Lancet 2007;370:859–77.
11. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851–8.
12. Patel V, Belkin GS, Chockalingam A, et al. Grand challenges: integrating mental health services into priority health care platforms. PLoS Med 2013;10:e1001448.
13. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. The Lancet 2009;374:609–19.
14. Mitchell AJ, Meader N, Bird V, et al. Clinical recognition and recording of alcohol disorders by clinicians in primary and secondary care: meta-analysis. Br J Psychiatry 2012;201:93–100.
15. Lund C, Tomlinson M, De Silva M, et al. PRIME: a programme to reduce the treatment gap for mental disorders in five low- and middle-income countries. PLoS Med 2012;9:e1001359.
16. Hanlon C, Luifel NP, Kathree T, et al. Challenges and opportunities for implementing integrated mental health care: a district level situation analysis from five low- and middle-income countries. PLoS One 2014;9:e88437.
17. De Silva MJ, Rathod SD, Hanlon C, et al. Evaluation of district mental healthcare plans: the PRIME consortium methodology. Br J Psychiatry 2016;208(Suppl 56):s63–s70.
18. Hanlon C, Medhin G, Selamu M, et al. Validity of brief screening questionnaires to detect depression in primary care in Ethiopia. J Affect Disord 2015;186:32–9.

19. Kohrt BA, Luitel NP, Acharya P, et al. Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal. BMC Psychiatry 2016;16:58.

20. Patel V, Araya R, Chowdhary N, et al. Detecting common mental disorders in primary care in India: a comparison of five screening questionnaires. Psychol Med 2008;38.

21. Bhana A, Rathod SD, Selolwile O, et al. The validity of the Patient Health Questionnaire for screening depression in chronic care patients in primary health care in South Africa. BMC Psychiatry 2015;15:118.

22. Nakku JEM, Rathod SD, Kizza D, et al. Validity and diagnostic accuracy of the Luganda version of the 9-item and 2-item Patient Health Questionnaire for detecting major depressive disorder in rural Uganda. Glob Ment Health 2016;3.

23. Nayak MB, Bond JC, Cherpitel C, et al. Detecting alcohol-related problems in developing countries: a comparison of 2 screening measures in India. Alcohol Clin Exp Res 2008;33:2057–66.

24. Pradhan B, Chappuis F, Baral D, et al. The alcohol use disorders identification test (AUDIT): validation of a Nepali version for the detection of alcohol use disorders and hazardous drinking in medical settings. Subst Abuse Treat Prev Policy 2012;7:42.

25. Myer L, Smit J, Roux LL, et al. Common mental disorders among HIV-infected individuals in South Africa: prevalence, predictors, and validation of brief psychiatric rating scales. AIDS Patient Care STDs 2008;22:147–58.

26. Saunders JB, Asland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993;88:791–804.

27. Chishinga N, Kinyanda E, Weiss HA, et al. Validation of brief screening tools for depressive and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Psychiatry 2011;11:75.

28. Breuer E, De Silva MJ, Shidiaye R, et al. Planning and evaluating mental health services in low- and middle-income countries using an inventory of change. Br J Psychiatry 2016;208(Suppl 56):s55–s62.

29. Fekadu A, Hanlon C, Medhin G, et al. Development of a scalable mental healthcare plan for a rural district in Ethiopia. Br J Psychiatry 2016;208(Suppl 56):s4–s12.

30. Shidiaye R, Shrivastava S, Murhar V, et al. Development and piloting of a plan for integrating mental health in primary care in Sehore district, Madhya Pradesh, India. Br J Psychiatry 2016;208(Suppl 56):s13–s20.

31. Jordans MJ, Luitel NP, Pokhrel P, et al. Development and pilot testing of a mental healthcare plan in Nepal. Br J Psychiatry 2016;208(Suppl 56):s21–s28.

32. Petersen I, Fairall L, Bhana A, et al. Integrating mental health into chronic care in South Africa: the development of a district mental healthcare plan. Br J Psychiatry 2016;208(Suppl 56):s29–s39.

33. Kigozi FN, Kizza D, Nakku J, et al. Development of a district mental healthcare plan in Uganda. Br J Psychiatry 2016;208(Suppl 56):s40–s46.

34. Fekadu A, Medhin G, Selamu M, et al. Recognition of depression by primary care clinicians in rural Ethiopia. BMC Fam Pract 2017;18:36.

35. Young AS, Klap R, Sherbourne CD, et al. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001;58:55.

36. Hutton C, Gunn J. Do longer consultations improve the management of psychological problems in general practice? A systematic literature review. BMC Health Serv Res 2007;7:71.

37. Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open 2017;7:e017902.

38. van Dijk CE, Verheij RA, Spreewenenberg P, et al. Impact of remuneration on guideline adherence: empirical evidence in general practice. Scand J Prim Health Care 2013;31:56–63.

39. Petersen I, Marais D, Abdulmalik J, et al. Strengthening mental health system governance in six low- and middle-income countries in Africa and South Asia: challenges, needs and potential strategies. Health Policy Plan 2017;32:699–709.

40. Upadhyaya N, Jordans MJ, Abdulmalik J, et al. Information systems for mental health in six low and middle income countries: cross country situation analysis. Int J Ment Health Syst 2016;10.

41. Babor TF, Higgins-Biddle JC, Saunders JB, et al. AUDIT: The Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization, 2001.

42. Robins LN, et al. The composite international diagnostic interview. Arch Gen Psychiatry 1988;45:1069–77.

43. Clement S, Brohan E, Jeffery D, et al. Development and psychometric properties the Barriers to Access to Care Evaluation scale (BACE) related to people with mental ill health. BMC Psychiatry 2012;12:36.

44. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.

45. Üstün TB, Kostanjsek N, Chatterji S, eds. Measuring health and disability: manual for WHO Disability Assessment Schedule WHODAS 2.0. Geneva: World Health Organization, 2010.